Proteomics International Laboratories announced today that it has signed an agreement to evaluate its PromarkerD test in clinical trials of Dimerix’s investigational chronic kidney disease drug DMX-200.
Article: Proteomics International to Test Kidney Disease Test as CDx for Investigational Treatment